Our understanding of mitochondrial diseases (defined restrictively as defects of the mitochondrial respiratory chain) is expanding rapidly. In this review, I will give the latest information on disorders affecting predominantly or exclusively skeletal muscle.
Introduction
The discussion that follows will be confined to the mitochondrial myopathies, that is, disorders of the respiratory chain affecting exclusively or predominantly skeletal muscle. Like other mitochondrial diseases, mitochondrial myopathies can also be classified genetically into two major groups: those due to mutations in mitochondrial DNA (mtDNA) and those due to mutations in nuclear DNA (nDNA). Two reviews on mitochondrial myopathies in the same journal had different but complementary slants. One review [1] focused on recent advances in the molecular bases of mitochondrial disorders and on pathogenetic mechanisms. The other [2] was a more practical review of diagnostic procedures, including clinical, morphologic, biochemical, and molecular studies (summarized in a flowchart). A third review by Wallace [3] focused on the role of mtDNA haplotypes in human adaptation to different environments and on therapeutic strategies. Yet a fourth review article [4] stressed the role of muscle involvement, and especially the all-toofrequent symptom of exercise intolerance, in patients with mitochondrial disease and the therapeutic role of aerobic exercise. In addition, the first comprehensive book on this subject, called Mitochondrial Medicine, has just been published [5] and one chapter is devoted to mitochondrial myopathies and neuropathies [6] .
Disorders due to mutations in mitochondrial DNA
Mutations in mtDNA that impair mitochondrial protein synthesis in toto include mtDNA rearrangements (deletions or duplications), mutations in tRNA genes, and mutations in rRNA genes. In contrast, and not surprisingly, mutations in individual protein-coding genes impair specifically the activity of the respiratory chain complex the subunit of which is mutated. Recent progress in the two types of mutations will be considered separately.
Single deletions of mitochondrial DNA
Single deletions of mtDNA are notoriously associated with sporadic progressive external ophthalmoplegia (PEO), either alone or in the context of the multisystemic Kearns-Sayre syndrome [6] . Starting from typical clinical features and using DNA extracted from buccal mucosa, the prevalence of large-scale mtDNA deletions was calculated to be 1.6 : 100 000 in a defined adult population of northern Finland [7] . As the authors found a similar prevalence in a neighboring Finnish province, they concluded that the rate at which de-novo mtDNA deletions occur is probably constant. Contrary to previous reports, Goios et al. [8] found no association between the incidence of large-scale deletions (including the 4977-bp 'common deletion') and specific mtDNA haplogroups [8] .
Mutations in tRNAs
Although muscle involvement is known to occur in mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS), the prevalence of myopathy had not been studied in a large and genetically homogeneous cohort. Kärrpä and coworkers [9 ] performed such a study in 50 patients with MELAS and the A3243G mutation in tRNA Leu(UUR) . They found that clinical myopathy was present in 50% of patients and manifested most commonly in the fifth decade, but varied considerably in severity and distribution, including mild to moderate limb weakness, ptosis, and ophthalmoplegia.
An unusual myopathic presentation of rheumatologic interest, with congenital distal arthrogryposis in two siblings, was associated with the T3271C mutation in tRNA Leu(UUR) , which typically causes MELAS [10] . Although the proposita did have a stroke at age 15, a younger brother had infantile arthrogryposis and attention deficit disorder but no stroke (at least, not yet) and there was no maternal family history of stroke.
Two unrelated patients, both harboring the 7472-insertion mutation in tRNA Ser(UCN) , had very different clinical presentations: one had a multisystem disorder akin to myoclonus epilepsy and ragged-red fibers (MERRF), whereas the other had a pure myopathy. The only difference at the molecular level was that the myopathic patient also had a novel homoplasmic A7472C transition in the same gene, which further lengthens the expanded homopolymeric C run caused by the insertion [11] . These findings raise the interesting possibility that concurrent mtDNA mutations may drastically influence the phenotype.
A long-standing controversy in mitochondrial circles has concerned the role of apoptosis in the pathogenesis of mitochondrial myopathies. An elegant study of muscle biopsies (all showing the typical mosaic pattern of raggedred fibers -RRFs) from 16 patients harboring large-scale mtDNA deletions and four patients with the A3243G MELAS mutation showed the following: apoptotic features were present in a small proportion of muscle fibers in 16 of the 20 biopsies; apoptosis occurred only in RRFs, that is, it was closely associated with mitochondrial proliferation; and, within RRFs, apoptosis was more common in fibers with high abundance of mutations [12] . Although the role of apoptosis in mitochondrial myopathies is likely to remain controversial, this paper clearly documents the occurrence of apoptosis and its association with mitochondrial proliferation and dysfunction.
A general feature of muscle biopsies from patients with mtDNA mutations impairing overall mitochondrial protein synthesis is the presence of cytochrome c oxidase (COX)-negative fibers: Barron and coworkers [13] studied the variation in their proportion in different muscles obtained post mortem from three patients with different mutations: heteroplasmic large-scale mtDNA deletion, heteroplasmic A3243G MELAS mutation, and homoplasmic T14709C mutation in tRNA Glu [13] . They concluded that the substantial variation in COX negativity within an individual section or between muscle blocks is not a diagnostic concern when COX-negative fibers are more than approximately 2%. Below this level, however, there is a high potential for diagnostic inaccuracy. Interestingly, they also observed variation in COX deficiency in muscle from the patient with the homoplasmic T14709C mutation, which cannot be due to variations in mutation load and must, therefore, be attributed to nuclear genes, possibly controlling mtDNA copy number.
Mutations in protein-coding genes
One protein-coding gene that is rapidly attaining the status of 'pathogenic hotspot' is ND5, which encodes subunit 5 of complex I. Although none of the mutations in ND5 causes a pure myopathy, muscle is involved in multisystem disorders including MELAS, Leber's hereditary optic neuropathy (LHON), Leigh syndrome, and MERRF, often overlapping in individual patients (for review, see [14] ). In contrast to mutations in ND5, mutations in ND1 and in ND4 have been associated with pure myopathy (for review, see [6]). A mutation in ND2 (G4810A) joins the list of mutations causing severe exercise intolerance (initially diagnosed as chronic fatigue syndrome) followed by mild ptosis and PEO [15] .
The importance of mutations in mtDNA COX genes in causing exercise intolerance and myoglobinuria was confirmed by three reports on four patients. Three of them were young adults with life-long exercise intolerance, exercise-related myalgia, and at least one episode of myoglobinuria; all three were sporadic cases harboring presumably somatic, heteroplasmic mutations confined to skeletal muscle and affecting COX I (G6708A) [16] , COX II (T7989C) [17] , and COX III (T9789C) [18] . The fourth patient, who harbored a heteroplasmic mutation (G7970T) in COX II, had a severe encephalomyopathy with short stature, bilateral cataracts, sensorineural hearing loss, myopathy, ataxia, cardiac arrhythmia, and depression [18] .
Disorders due to mutations in nuclear DNA
Most inherited mitochondrial diseases are due to mutations in nuclear genes encoding a multitude of proteins (about 1500) with a variety of housekeeping or specialized functions, which are targeted to mitochondria. A problem in identifying Mendelian mitochondriopathies is that we only know about half of these genes. Through the integrated analysis of eight experimentally and computationally generated genome-scale data sets, Calvo and coworkers [19 ] have expanded the catalog of nuclear genes, presumably encoding mitochondrial proteins, and have identified several candidate genes for mitochondrial diseases. To help clarify the 'dialogue' between the nuclear and mitochondrial genomes and the pathogenesis of mitochondrial diseases, microarray technology is being employed to study changes in the expression of multiple genes of both genomes in response to specific mitochondrial defects [20, 21] .
Mutations in nDNA directly affecting the mitochondrial respiratory chain fall into three major groups. First, 'direct hits', namely, mutations in genes that encode subunits of respiratory chain complexes: these are known for complexes I and II, and coenzyme Q10 (CoQ10). Second, 'indirect hits', namely, mutations in genes encoding ancillary proteins that are needed for the correct assembly and function of respiratory chain complexes. Third, defects in intergenomic signaling, that is, mutations in nuclear genes that control the abundance and quality of mtDNA and result in multiple deletions of mtDNA, mtDNA depletion, or both conditions at once.
Mutations in respiratory chain subunits
Although the first patients with muscle CoQ10 deficiency were reported in 1989 [22] , interest in this entity was recently rekindled by the descriptions of different clinical phenotypes [23] . A 'pure' mitochondrial myopathy due to CoQ10 deficiency was described by Lalani et al. [24] in an 11-year-old boy with recent subacute onset of exercise intolerance and proximal weakness. Muscle biopsy showed RRF and lipid storage and CoQ10 concentration in muscle was 46% of normal. Oral CoQ10 supplementation (300 mg daily) resulted in 'sustained clinical improvement' and normalization of both serum creatine kinase and lactate levels. Isolated myopathy due to primary muscle CoQ10 deficiency may be underdiagnosed because Horvath et al. [25 ] recently reported three unrelated and sporadic patients with mitochondrial myopathy and lipid storage responsive to CoQ10 supplementation.
Another presentation of CoQ10 deficiency amenable to therapy is a severe and -if untreated -rapidly fatal encephalomyopathy of infancy, characteristically associated with nephrotic syndrome. Two families have been reported [26, 27] , and we have studied a third family [28] . The propositus of our family was a 33-month-old boy, the son of first cousins, who was hospitalized at 12 months because of a severe nephrotic syndrome. Neurological examination showed severe hypotonia and mild psycho-motor delay. At 18 months, he had marked weakness, psychomotor regression, tremor, and developed status epilepticus. A muscle biopsy at 22 months of age showed only mild mitochondrial proliferation with the succinate dehydrogenase stain, but decreased complex III activity and CoQ10 deficiency (37% of the normal mean). Oral supplementation (30 mg/kg/day) dramatically improved the neurological picture but not the renal dysfunction. Interestingly, the first mutation in a CoQ10 synthetic gene has been documented in this family, thus proving the existence of primary CoQ10 deficiency [29 ] . The mutated gene (COQ2) encodes para-hydroxybenzoatepolyprenyl transferase, the second enzyme in the biosynthetic pathway of CoQ10, which mediates the conjugation of the benzoquinone ring with the decaprenyl side chain. The homozygous mutation (A890G) in COQ2 changes a highly conserved tyrosine to a cysteine (Y297C) within a predicted transmembrane domain. Radioisotope assays confirmed a severe defect of CoQ10 biosynthesis.
There is controversy concerning the pathogenesis of 'statin myopathy', a iatrogenic disorder ranging in severity from asymptomatic hyperCKemia to myalgia and cramps, to fixed weakness, or -in extreme cases -to acute muscle breakdown (rhabdomyolysis) and myoglobinuria [30] . We have explored the possibility that statin myopathy may be due to muscle CoQ10 deficiency because statins inhibit the synthesis of mevalonate, which is a common precursor of both cholesterol and CoQ10. We found that muscle CoQ10 concentration in 18 patients with statin-related myopathy was not significantly different from controls, although in 56% of patients CoQ10 values were below 1 standard deviation of the normal mean [31 ] .
Mutations in ancillary proteins
Mendelian disorders due to defects in complexes III, IV and V are not due to 'direct hits', that is, to mutations in genes encoding subunits of these complexes. Rather, they are due to 'murder by proxy', that is, to mutations in genes encoding proteins needed for the proper assembly or function of the complexes. Ogilvie and coworkers [32 ] have now identified pathogenic mutations in the first assembly gene for complex I (B17.2L) associated with cavitating leukoencephalopathy.
None of the known mutations in ancillary protein, including COX10, causes isolated myopathy, although muscle is almost invariably involved in these -usually infantile and generalized -disorders. Targeted disruption of the COX10 gene in skeletal muscle of mice, however, produced a COX-deficient myopathy [33] . Although COX activity in muscle was negligible, surprisingly these knockout mice were still alive at 2.5 months and their muscles were able to contract at 80 to 100% of control maximal forces and showed no signs of oxidative damage or apoptosis.
Defects in intergenomic signaling
These are Mendelian disorders in which mutations in nuclear genes cause qualitative (multiple deletions) or quantitative (depletion) alterations of mtDNA.
The most important new information for the myologist concerns genes whose mutations cause PEO. Of these, POLG, which encodes the mitochondrial polymerase g, is especially interesting because mutations in this gene appear to be the most common causes of PEO and because they can cause not only autosomal dominant PEO (adPEO) but also autosomal recessive PEO (arPEO) [34] . The spectrum of clinical phenotypes associated with POLG mutations was reviewed in two back-to-back papers and an editorial in Brain [35,36 ,37 ].
The search for nuclear genes associated with PEO is not over because, rather surprisingly, mutations in POLG, Twinkle, and ANT1 were uncommon in sporadic patients with PEO and multiple mtDNA deletions in muscle [38] . This search is already bearing fruit as a heterozygous dominant mutation (G1352A) has been identified in POLG2, the gene encoding Polg2, the dimeric accessory subunit of Polg proper (or Polg1) in a 60-year-old woman with adult-onset ptosis, ophthalmoplegia, cardiac conduction defect, increased serum creatine kinase, borderline blood lactate, and a family history suggestive of autosomal dominant inheritance [39 ] . Her muscle biopsy showed scattered COX-negative fibers and multiple mtDNA deletions by long-range polymerase chain reaction. Biochemical studies of the purified recombinant mutant protein showed impaired stimulation of polg1 due to altered subunit interaction.
Mutations in POLG (encoding polg1) are also a common cause of mtDNA depletion, especially of the hepatocerebral variants known as Alpers syndrome [40] [41] [42] . Another hepatocerebral syndrome due to mtDNA depletion was recently attributed, through an integrative genomics approach [19 ] , to a new gene, MPV17, which encodes a protein localized in the inner mitochondrial membrane (not in the peroxisomes, as previously thought) and whose exact function remains to be clarified [43 ] . Three families were described with MPV17 mutations, one from southern Italy, one from Morocco, and one from Canada. In the Italian family, two siblings died in infancy of hepatic failure, but liver transplantation in a third sibling and dietary control of hypoglycemia in a fourth sibling allowed long-term survival, although the child on a dietary regimen at 9 years of age developed neurological symptoms and brain lesions by magnetic resonance imaging. In the Moroccan and Canadian family, patients died in infancy of hepatic failure. Inter-estingly, MPV17 is the first protein involved in mtDNA depletion that does not play a role in the homeostasis of the mitochondrial nucleoside/nucleotide pool. This is important because a recent search for mutations in another candidate gene involved in mitochondrial nucleotide pool homeostasis, PPA2, encoding a mitochondrial pyrophosphatase (PPase2), was fruitless in 13 children with undefined mtDNA depletion syndromes [44] . Although skeletal muscle is typically spared in hepatocerebral syndromes, it was prominently -but not exclusively -involved in an mtDNA depletion syndrome due to mutations in the SUCLA2 gene, which encodes the b subunit of the mitochondrial matrix enzyme succinyl-CoA synthetase (SCS-A) [45] . SCS-A is a heterodimer that catalyzes the formation of succinate and ATP from succinyl-CoA and ADP in the Krebs cycle. Discoveries of the MPV17 and SUCLA2 gene mutations are important because there are many children with mtDNA depletion in muscle or liver that is not explained by mutations in the thymidine kinase 2 (TK2), deoxyguanosine kinase (DGUOK) or polymerase g (POLG) genes [34] .
To determine the mtDNA copy number threshold below which dysfunction (using COX histochemistry as a marker) ensues in muscle, Durham and coworkers [46] measured the absolute number of mtDNA within single muscle fibers from two patients with TK2 deficiency and found that TK2-deficient fibers containing more than 0.01 mtDNA/mm 3 retained some COX activity. This threshold explains the mosaic histochemical pattern of ragged-red and COX-deficient fibers seen in patients with mtDNA depletion myopathy.
Defects of the lipid milieu
The components of the respiratory chain are embedded in the inner mitochondrial membrane, which is not a mere scaffold, but a participant in oxidative phosphorylation. This is largely due to cardiolipin, an acidic phospholipid uniquely abundant in the inner mitochondrial membrane. The synthesis of cardiolipin is markedly decreased and qualitatively altered in Barth syndrome [47] [48] [49] , an X-linked recessive disorder characterized by cardiomyopathy, mitochondrial myopathy, growth retardation, and cyclic neutropenia. The gene for Barth syndrome, G4.5, encodes a family of proteins called tafazzins, which share conserved regions with acyltransferases. A reasonable pathogenic scenario for Barth syndrome is that a mutant acyltransferase encoded by G4.5 leads to altered synthesis of cardiolipin, which impairs oxidative phosphorylation. Although there is still no firm documentation that respiratory chain function is defective in muscle from Barth syndrome patients, this concept is made more plausible by the close structural and functional relationship between cardiolipin and COX documented in bovine heart COX by photolabeling studies [50] and by evidence that cardiolipin is essential for the association of complexes III and IV into a supercomplex in intact yeast mitochondria [51] .
Conclusions
The rapid progress in our understanding of mitochondrial diseases has not slackened. In the field of mitochondrial myopathies, the importance of mutations in proteincoding genes of mtDNA in causing the often-elusive syndrome of exercise intolerance has been confirmed. Increasing numbers of homoplasmic mutations in mtDNA tRNA genes have forced us to revise the concept that only heteroplasmic mtDNA mutations are pathogenic.
Among Mendelian mitochondrial myopathies, CoQ10 deficiency is associated with increased frequency not only with encephalomyopathies but also with isolated myopathies and the first mutation in a CoQ10 synthetic gene has been documented, an important proof of principle for the existence of primary CoQ10 deficiency. The importance of a timely diagnosis of CoQ10 deficiency cannot be underestimated because these disorders are responsive to CoQ10 supplementation. The role -if any -of CoQ10 deficiency in statin-related myopathy is being explored with studies of human muscle biopsies. The molecular etiologies of mtDNA depletion syndromes are expanding and mutations in the SUCLA2 gene and MPV17 are newly recognized causes of mtDNA depletion.
Unfortunately, although interesting and often imaginative therapeutic strategies have been successful in vitro, therapy for mitochondrial myopathies remains woefully inadequate.
